Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Chemoimmunotherapy

(2010) Leisha A. Emens   CANCER JOURNAL

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas

(2010) Anne Clavreul et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

(2010) Hilko Ardon et al.   JOURNAL OF NEURO-ONCOLOGY

Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study

(2010) Walter Stummer et al.   JOURNAL OF NEUROSURGERY

Dendritic Cell Therapy of High-Grade Gliomas

(2009) Stefaan Van Gool et al.   BRAIN PATHOLOGY

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

(2009) Oliver M. Grauer et al.   BRAIN PATHOLOGY

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model

(2009) T.-G. Kim et al.   Clinical and Vaccine Immunology

Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial

(2009) Stuart A. Grossman et al.   JOURNAL OF CLINICAL ONCOLOGY

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

(2009) H. Ardon et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

(2008) C. J. Wheeler et al.   CANCER RESEARCH

Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

(2008) S. De Vleeschouwer et al.   CLINICAL CANCER RESEARCH

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy

(2007) David G. Walker et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY